Advertisement.
Advertisement.
Advertisement
Advertisement.
APTO Aptose Biosciences Inc
6,963
| Market Cap | $10.29M |
| Volume | 95,391.00 |
| 52-Wk High | $5.10 |
| 52-Wk Low | $0.5684 |
Aptose Biosciences Faces Nasdaq Delisting Challenge
TipRanks Financial Blog•7 days ago
Aptose Biosciences (APS) has provided an announcement. Aptose Biosciences Inc. has been notified by Nasdaq that their stock has not met the minimum...
Share to Feed
HC Wainwright reissued their buy rating on shares of Aptose Biosciences (NASDAQ:APTO - Free Report) (TSE:APS) in a research note published on Wednesday morning, Benzinga reports. HC Wainwright...
Ticker Report•4 months ago
Aptose Biosciences (NASDAQ:APTO - Get Free Report) (TSE:APS) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on...
Zolmax•4 months ago
Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) was the recipient of a large decline in short interest in March. As of March 15th, there was short interest totalling 50,200...
Ticker Report•4 months ago
Shares of Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) have earned an average rating of Buy from the five research firms that are currently covering the...
Ticker Report•4 months ago
Related Stocks: NAS:APTO...
GuruFocus•4 months ago
Tuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired...
Globe Newswire•4 months ago
Aptose Biosciences Q4 2023 Earnings Preview...
SeekingAlpha.com: All News•4 months ago
Aptose Biosciences Inc. (NASDAQ:APTO Get Free Report) (TSE:APS) has earned a consensus rating of Buy from the six brokerages that are presently covering the stock, MarketBeat...
Zolmax•4 months ago